董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| J. Daniel Plants | 男 | Chairperson | 54 | 18.33万美元 | 未持股 | 2021-04-01 |
| Katherine S. Zanotti | 女 | Director | 66 | 14.87万美元 | 未持股 | 2021-04-01 |
| Timothy J. O'Shea | 男 | Director | 68 | 15.40万美元 | 未持股 | 2021-04-01 |
| David H. Mowry | 男 | Chief Executive Officer,Director | 58 | 133.46万美元 | 未持股 | 2021-04-01 |
| Gregory Barrett | 男 | Director | 67 | 16.09万美元 | 未持股 | 2021-04-01 |
| Joseph E. Whitters | 男 | Director | 63 | 15.69万美元 | 未持股 | 2021-04-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| R. Jason Richey | 男 | President | 47 | 113.86万美元 | 未持股 | 2021-04-01 |
| Rohan Seth | 男 | Chief Financial Officer | 43 | 102.24万美元 | 未持股 | 2021-04-01 |
| David H. Mowry | 男 | Chief Executive Officer,Director | 58 | 133.46万美元 | 未持股 | 2021-04-01 |
董事简历
中英对照 | 中文 | 英文- J. Daniel Plants
-
J. Daniel Plants，2015年1月以来，他曾担任我们的董事会成员。他一直担任Voce Capital Management LLC的管理合伙人（2009年以来）。创立Voce Capital Management LLC之前，他曾担任领先的华尔街公司的多种职务，其中包括Goldman Sachs、JPMorgan Chase的投资银行的执行职务，以及Sullivan & Cromwell的公司律师。他也是the Bay Area Urban Debate League（旧金山慈善组织，致力于扩大地区青年成为明智领导人的机会）的联席创始人。他曾担任机构的副主席（从2008年到2012年）。他持有University of Michigan Law School的法学博士学位，以及Baylor University的学士学位。
J. Daniel Plants was appointed Chairperson of the Board in October 2016 and has been a member of the Board since January 2015. Mr. Plants has been Managing Partner of Voce Capital Management LLC since 2009. Prior to founding Voce Capital Management, Mr. Plants held a number of positions at leading Wall Street firms, including executive roles in investment banking at Goldman Sachs and JPMorgan Chase, and as a corporate attorney with Sullivan & Cromwell. Mr. Plants cofounded The Bay Area Urban Debate League and served as its Vice Chairman from 2008 to 2012. Mr. Plants holds a Juris Doctorate degree from University of Michigan Law School and an undergraduate degree from Baylor University. - J. Daniel Plants，2015年1月以来，他曾担任我们的董事会成员。他一直担任Voce Capital Management LLC的管理合伙人（2009年以来）。创立Voce Capital Management LLC之前，他曾担任领先的华尔街公司的多种职务，其中包括Goldman Sachs、JPMorgan Chase的投资银行的执行职务，以及Sullivan & Cromwell的公司律师。他也是the Bay Area Urban Debate League（旧金山慈善组织，致力于扩大地区青年成为明智领导人的机会）的联席创始人。他曾担任机构的副主席（从2008年到2012年）。他持有University of Michigan Law School的法学博士学位，以及Baylor University的学士学位。
- J. Daniel Plants was appointed Chairperson of the Board in October 2016 and has been a member of the Board since January 2015. Mr. Plants has been Managing Partner of Voce Capital Management LLC since 2009. Prior to founding Voce Capital Management, Mr. Plants held a number of positions at leading Wall Street firms, including executive roles in investment banking at Goldman Sachs and JPMorgan Chase, and as a corporate attorney with Sullivan & Cromwell. Mr. Plants cofounded The Bay Area Urban Debate League and served as its Vice Chairman from 2008 to 2012. Mr. Plants holds a Juris Doctorate degree from University of Michigan Law School and an undergraduate degree from Baylor University.
- Katherine S. Zanotti
-
Katherine S. Zanotti自2019年2月以来一直担任我们的董事会成员。她曾于2009年8月至2018年6月担任Arbonne International的首席执行官。自2010年3月以来，Zanotti女士还担任Natural Products Group的董事长，该公司是Arbonne，Natures Gate和LeVlad的控股公司。从2002年7月到2006年3月，她担任麦当劳公司的营销高级副总裁。Zanotti女士是宝洁公司的退休副总裁，最近担任北美制药业务和公司女性健康平台的副总裁兼总经理。Zanotti女士目前担任Exact Sciences的董事会成员，并担任Xavier University的董事会成员。她此前曾担任希尔罗控股公司（医疗技术和相关服务的全球制造商和供应商）、Mentor Corporation（医疗设备公司）、Alberto Culver Company（个人护理产品公司）、Third Wave Technologies，Inc.（分子诊断公司）的董事。她在乔治敦大学获得经济学和工作室美术学士学位，并在泽维尔大学获得市场营销和金融工商管理硕士学位。
Katherine S. Zanotti has served as a member of our Board since February 2019. She previously served as chief executive officer of Arbonne International from August 2009 until June 2018. Ms. Zanotti has also served as Chairman of Natural Products Group the holding company of Arbonne, Natures Gate, and Levlad since March 2010. From July 2002 to March 2006 she served as senior vice president of marketing at McDonald's Corporation. Ms. Zanotti is a retired vice president of the Procter & Gamble Company and most recently served as vice president and general manager of the North American pharmaceutical business and the corporate women's health platform. Ms. Zanotti currently serves on the Board of Exact Sciences, and as a member of the Board of Trustees of Xavier University. She previously served as a director of Hill-Rom Holdings, Inc., a worldwide manufacturer and provider of medical technologies and related services; Mentor Corporation, a medical device company; Alberto Culver Company, a personal care products company; and Third Wave Technologies, Inc., a molecular diagnostics company. She earned a bachelor's degree in economics and studio fine arts from Georgetown University and an MBA in marketing and finance from Xavier University. - Katherine S. Zanotti自2019年2月以来一直担任我们的董事会成员。她曾于2009年8月至2018年6月担任Arbonne International的首席执行官。自2010年3月以来，Zanotti女士还担任Natural Products Group的董事长，该公司是Arbonne，Natures Gate和LeVlad的控股公司。从2002年7月到2006年3月，她担任麦当劳公司的营销高级副总裁。Zanotti女士是宝洁公司的退休副总裁，最近担任北美制药业务和公司女性健康平台的副总裁兼总经理。Zanotti女士目前担任Exact Sciences的董事会成员，并担任Xavier University的董事会成员。她此前曾担任希尔罗控股公司（医疗技术和相关服务的全球制造商和供应商）、Mentor Corporation（医疗设备公司）、Alberto Culver Company（个人护理产品公司）、Third Wave Technologies，Inc.（分子诊断公司）的董事。她在乔治敦大学获得经济学和工作室美术学士学位，并在泽维尔大学获得市场营销和金融工商管理硕士学位。
- Katherine S. Zanotti has served as a member of our Board since February 2019. She previously served as chief executive officer of Arbonne International from August 2009 until June 2018. Ms. Zanotti has also served as Chairman of Natural Products Group the holding company of Arbonne, Natures Gate, and Levlad since March 2010. From July 2002 to March 2006 she served as senior vice president of marketing at McDonald's Corporation. Ms. Zanotti is a retired vice president of the Procter & Gamble Company and most recently served as vice president and general manager of the North American pharmaceutical business and the corporate women's health platform. Ms. Zanotti currently serves on the Board of Exact Sciences, and as a member of the Board of Trustees of Xavier University. She previously served as a director of Hill-Rom Holdings, Inc., a worldwide manufacturer and provider of medical technologies and related services; Mentor Corporation, a medical device company; Alberto Culver Company, a personal care products company; and Third Wave Technologies, Inc., a molecular diagnostics company. She earned a bachelor's degree in economics and studio fine arts from Georgetown University and an MBA in marketing and finance from Xavier University.
- Timothy J. O'Shea
-
Timothy J. O'Shea自2004年4月一直是公司的董事会成员。奥谢先生自2008年以来一直在Oxo资本公司工作，并担任总经理。从1995年到2008年，他担任过波士顿科学公司的各种管理职务，包括在2000至2008年所担任的业务开发部的公司副经理。奥谢先生获得了底特律大学的历史学学士学位。
Timothy J. O'Shea has served as a member of our board of directors since April 2004. Mr. O'Shea has been with Oxo Capital since 2008 and serves as a managing director. From 1995 to 2008 he served in a variety of management positions at Boston Scientific, including Corporate Vice President of Business Development from 2000 to 2008. Mr. O'Shea holds a B.A. in history from the University of Detroit. - Timothy J. O'Shea自2004年4月一直是公司的董事会成员。奥谢先生自2008年以来一直在Oxo资本公司工作，并担任总经理。从1995年到2008年，他担任过波士顿科学公司的各种管理职务，包括在2000至2008年所担任的业务开发部的公司副经理。奥谢先生获得了底特律大学的历史学学士学位。
- Timothy J. O'Shea has served as a member of our board of directors since April 2004. Mr. O'Shea has been with Oxo Capital since 2008 and serves as a managing director. From 1995 to 2008 he served in a variety of management positions at Boston Scientific, including Corporate Vice President of Business Development from 2000 to 2008. Mr. O'Shea holds a B.A. in history from the University of Detroit.
- David H. Mowry
-
David H. Mowry，2013年2月至今，担任本公司的总裁、首席执行官；2013年6月至今，担任执行董事。他于2011年7月加入本公司，担任首席运营官；2012年11月，他被任命为临时总裁、首席执行官；2013年2月，正式担任总裁、首席执行官。他有着超过24年的医疗器械行业的经验。加入本公司之前，2010年7月至2011年7月，他担任Covidien plc的全球神经血管部门总裁，这是一个国际性的医疗产品供应商。2010年1月至2010年7月，他担任ev3 Inc的高级副总裁、全球心血管总裁，这是一个全球性的血管内置产品供应商，在2010年7月被Covidien收购。2007年8月至2010年1月，他是ev3的全球运营高级副总裁。此前，2006年11月至2007年10月，他担任ev3心血管理运营副总裁。加入ev3之前，2002年2月至2006年11月，他在 Zimmer Holdings的Zimmer Spine分部担任运营与物流副总裁，这是一个重建与脊柱植入物、外伤及相关整形外科产品的公司。加入Zimmer之前，他是医疗器械公司HeartStent Corp的总裁、首席运营官。他毕业于纽约的United States Military Academy in West Point，获得工程与数学学位。
David H. Mowry was appointed as the Company's Chief Executive Officer and a member of the Board on July 8 2019. Prior to joining Cutera, from May 2016 to October 2018 Mr. Mowry served as President and Chief Executive Officer, as well as a member of the Board of Directors, of Vyaire Medical, a global leader in the respiratory diagnostics, ventilation, and anesthesia delivery and patient monitoring market segments. Prior to his assignment at Vyaire, Mr. Mowry served as Executive Vice President and Chief Operating Officer and member of the Board of Directors of Wright Medical Group N.V., a global medical device company focused on extremities and biologics products, from October 2015 to May 2016 and during this time period he was also a member of the Board of Directors of EndoChoice Holdings, Inc., a company focused on the manufacturing and commercialization of platform technologies relating to the treatment of gastrointestinal conditions. Prior to Mr. Mowry's assignment at Wright Medical Group, he served as President and Chief Executive Officer and member of the Board of Directors of Tornier N.V. from February 2013 until October 2015 at which time Tornier and Wright Medical Group merged, and prior to that, as Chief Operating Officer of Tornier from 2011 to 2013. Within the spine industry, Mr. Mowry served as Vice President of Operations and Logistics at Zimmer Spine from February 2002 until October 2006. Mr. Mowry has held executive leadership positions over his thirty year medical device career at Covidien plc, ev3 Inc. and Zimmer Spine, Inc. Mr. Mowry is on the Board of directors of Alphatec Holdings, Inc., a public medical technology company that designs, develops, and markets products for the surgical treatment of spine disorders. Mr. Mowry received a B.S. degree in Engineering from the United States Military Academy at West Point. - David H. Mowry，2013年2月至今，担任本公司的总裁、首席执行官；2013年6月至今，担任执行董事。他于2011年7月加入本公司，担任首席运营官；2012年11月，他被任命为临时总裁、首席执行官；2013年2月，正式担任总裁、首席执行官。他有着超过24年的医疗器械行业的经验。加入本公司之前，2010年7月至2011年7月，他担任Covidien plc的全球神经血管部门总裁，这是一个国际性的医疗产品供应商。2010年1月至2010年7月，他担任ev3 Inc的高级副总裁、全球心血管总裁，这是一个全球性的血管内置产品供应商，在2010年7月被Covidien收购。2007年8月至2010年1月，他是ev3的全球运营高级副总裁。此前，2006年11月至2007年10月，他担任ev3心血管理运营副总裁。加入ev3之前，2002年2月至2006年11月，他在 Zimmer Holdings的Zimmer Spine分部担任运营与物流副总裁，这是一个重建与脊柱植入物、外伤及相关整形外科产品的公司。加入Zimmer之前，他是医疗器械公司HeartStent Corp的总裁、首席运营官。他毕业于纽约的United States Military Academy in West Point，获得工程与数学学位。
- David H. Mowry was appointed as the Company's Chief Executive Officer and a member of the Board on July 8 2019. Prior to joining Cutera, from May 2016 to October 2018 Mr. Mowry served as President and Chief Executive Officer, as well as a member of the Board of Directors, of Vyaire Medical, a global leader in the respiratory diagnostics, ventilation, and anesthesia delivery and patient monitoring market segments. Prior to his assignment at Vyaire, Mr. Mowry served as Executive Vice President and Chief Operating Officer and member of the Board of Directors of Wright Medical Group N.V., a global medical device company focused on extremities and biologics products, from October 2015 to May 2016 and during this time period he was also a member of the Board of Directors of EndoChoice Holdings, Inc., a company focused on the manufacturing and commercialization of platform technologies relating to the treatment of gastrointestinal conditions. Prior to Mr. Mowry's assignment at Wright Medical Group, he served as President and Chief Executive Officer and member of the Board of Directors of Tornier N.V. from February 2013 until October 2015 at which time Tornier and Wright Medical Group merged, and prior to that, as Chief Operating Officer of Tornier from 2011 to 2013. Within the spine industry, Mr. Mowry served as Vice President of Operations and Logistics at Zimmer Spine from February 2002 until October 2006. Mr. Mowry has held executive leadership positions over his thirty year medical device career at Covidien plc, ev3 Inc. and Zimmer Spine, Inc. Mr. Mowry is on the Board of directors of Alphatec Holdings, Inc., a public medical technology company that designs, develops, and markets products for the surgical treatment of spine disorders. Mr. Mowry received a B.S. degree in Engineering from the United States Military Academy at West Point.
- Gregory Barrett
-
Gregory Barrett自2011年10月一直是公司董事会成员。从2013年9月起，巴雷特一直DFINE公司，一家私营医疗器械设备公司的总裁兼首席执行官。贝瑞特先生是B’ARRX医药公司的董事长兼总裁兼首席执行官，该公司是一家私营医疗器械公司，被一家生产治疗胃肠疾病产品的制造商和分销商所收购。在2004年2月之前，即从2001年1月至2003年8月。巴雷特先生担任过ACMI公司，一家医学可视化和能源系统开发商的总裁兼首席执行官； 担任过波士顿科学公司的集团副总裁；担任过Orthofix公司（前身为美国医疗电子公司）及百特医疗用品的全球销售和营销的副总经理。巴雷特先生获得了奥斯汀市德克萨斯大学市场营销的学士学位。
Gregory Barrett has served as a member of our Board since October 2011. Mr. Barrett also serves on the Board of Global Kinetics, Inc and Aqua Medical, Inc. From September 2013 to October 2016 Mr. Barrett was the President and CEO of DFINE, Inc., a private medical device company that was acquired by Merit Medical. Mr. Barrett was the Chairperson, President and CEO of BÂRRX Medical, Inc., a private medical device company that was acquired by Covidien, a manufacturer and distributor of products to treat gastrointestinal diseases. Prior to joining BÂRRX Medical in February 2004 from January 2001 through August 2003 Mr. Barrett served as President and CEO of ACMI Corporation, a developer of medical visualization and energy systems; Group Vice President at Boston Scientific Corporation; Vice President, Global Sales and Marketing at both Orthofix Corporation formerly American Medical Electronics and Baxter Healthcare. Mr. Barrett holds a B.A. in Marketing from the University of Texas, Austin. - Gregory Barrett自2011年10月一直是公司董事会成员。从2013年9月起，巴雷特一直DFINE公司，一家私营医疗器械设备公司的总裁兼首席执行官。贝瑞特先生是B’ARRX医药公司的董事长兼总裁兼首席执行官，该公司是一家私营医疗器械公司，被一家生产治疗胃肠疾病产品的制造商和分销商所收购。在2004年2月之前，即从2001年1月至2003年8月。巴雷特先生担任过ACMI公司，一家医学可视化和能源系统开发商的总裁兼首席执行官； 担任过波士顿科学公司的集团副总裁；担任过Orthofix公司（前身为美国医疗电子公司）及百特医疗用品的全球销售和营销的副总经理。巴雷特先生获得了奥斯汀市德克萨斯大学市场营销的学士学位。
- Gregory Barrett has served as a member of our Board since October 2011. Mr. Barrett also serves on the Board of Global Kinetics, Inc and Aqua Medical, Inc. From September 2013 to October 2016 Mr. Barrett was the President and CEO of DFINE, Inc., a private medical device company that was acquired by Merit Medical. Mr. Barrett was the Chairperson, President and CEO of BÂRRX Medical, Inc., a private medical device company that was acquired by Covidien, a manufacturer and distributor of products to treat gastrointestinal diseases. Prior to joining BÂRRX Medical in February 2004 from January 2001 through August 2003 Mr. Barrett served as President and CEO of ACMI Corporation, a developer of medical visualization and energy systems; Group Vice President at Boston Scientific Corporation; Vice President, Global Sales and Marketing at both Orthofix Corporation formerly American Medical Electronics and Baxter Healthcare. Mr. Barrett holds a B.A. in Marketing from the University of Texas, Austin.
- Joseph E. Whitters
-
Joseph E. Whitters，自2018年7月起担任Accuray Incorporated董事会成员。自2005年以来，惠特斯一直担任私募股权公司Frazier Healthcare的顾问/顾问。从1986年到2005年，Whitters先生在First Health Group Corp.（一家上市的管理式医疗公司）担任各种职务，最近担任其首席财务官。此前，他还曾在1984年至1986年期间担任公开上市的医疗保健管理公司United Healthcare Corp的财务总监。在此之前，Whitters先生曾担任上市卡车运输公司Overland Express的会计和税务经理，他的公共会计职业生涯始于Peat Marwick（现毕马威）。Whitters曾在多家上市公司的董事会和审计委员会任职，其中包括全球美容设备公司Cutera, Inc.，从2019年2月至2023年6月，InfuSystem Holdings，Inc.，一家输液泵及相关产品和服务的公开交易供应商，从2012年4月至2019年5月；医疗保健和安全技术解决方案私营公司，从2017年10月至2018年6月；PRGX全球，Inc.，一家恢复审计和支出分析服务的私营供应商，从2013年2月至2021年3月；SPARK网络，一家优质在线约会网站和移动应用程序的私营运营商，2021年7月至2024年2月；以及私营空中医疗运输和空中旅游公司Air Methods公司，2016年3月至2017年4月。Whitters还曾是多家私营公司的顾问或董事会成员。Whitters先生拥有路德学院会计学学士学位。
Joseph E. Whitters has served as a member of Board since July 2018. Mr. Whitters has been an advisor/consultant to Frazier Healthcare, a private equity firm, since 2005. From 1986 to 2005, Mr. Whitters served in vario capacities with First Health Group Corp., a publicly traded managed care company, most recently as its Chief Financial Officer. He also previoly served as the Controller for United Healthcare Corp, a publicly traded health care management company, from 1984 to 1986. Prior to that, Mr. Whitters served as the Manager of Accounting and Taxation for Overland Express, a publicly traded trucking company, and he began his career in public accounting with Peat Marwick (now KPMG). Whitters has served on the boards of directors and audit committees of vario public companies, including Cutera, Inc., a global aesthetics device company, from February 2019 through June 2023; Infystem Holdings, Inc., a publicly traded provider of infion pumps and related products and services, from April 2012 through May 2019; Analogic Corporation, a private healthcare and security technology solutions company, from October 2017 through June 2018; PRGX Global, Inc., a private provider of recovery audit and spend analytics services, from February 2013 to March 2021; Spark Networks, a private operator of premium online dating sites and mobile applications, from July 2021 to February 2024; and Air Methods Corp., a private air medical transportation and air tism company, from March 2016 through April 2017. Mr. Whitters has also been an advisor or board member of several private companies. Mr. Whitters holds a B.A. in Accounting from Luther College. - Joseph E. Whitters，自2018年7月起担任Accuray Incorporated董事会成员。自2005年以来，惠特斯一直担任私募股权公司Frazier Healthcare的顾问/顾问。从1986年到2005年，Whitters先生在First Health Group Corp.（一家上市的管理式医疗公司）担任各种职务，最近担任其首席财务官。此前，他还曾在1984年至1986年期间担任公开上市的医疗保健管理公司United Healthcare Corp的财务总监。在此之前，Whitters先生曾担任上市卡车运输公司Overland Express的会计和税务经理，他的公共会计职业生涯始于Peat Marwick（现毕马威）。Whitters曾在多家上市公司的董事会和审计委员会任职，其中包括全球美容设备公司Cutera, Inc.，从2019年2月至2023年6月，InfuSystem Holdings，Inc.，一家输液泵及相关产品和服务的公开交易供应商，从2012年4月至2019年5月；医疗保健和安全技术解决方案私营公司，从2017年10月至2018年6月；PRGX全球，Inc.，一家恢复审计和支出分析服务的私营供应商，从2013年2月至2021年3月；SPARK网络，一家优质在线约会网站和移动应用程序的私营运营商，2021年7月至2024年2月；以及私营空中医疗运输和空中旅游公司Air Methods公司，2016年3月至2017年4月。Whitters还曾是多家私营公司的顾问或董事会成员。Whitters先生拥有路德学院会计学学士学位。
- Joseph E. Whitters has served as a member of Board since July 2018. Mr. Whitters has been an advisor/consultant to Frazier Healthcare, a private equity firm, since 2005. From 1986 to 2005, Mr. Whitters served in vario capacities with First Health Group Corp., a publicly traded managed care company, most recently as its Chief Financial Officer. He also previoly served as the Controller for United Healthcare Corp, a publicly traded health care management company, from 1984 to 1986. Prior to that, Mr. Whitters served as the Manager of Accounting and Taxation for Overland Express, a publicly traded trucking company, and he began his career in public accounting with Peat Marwick (now KPMG). Whitters has served on the boards of directors and audit committees of vario public companies, including Cutera, Inc., a global aesthetics device company, from February 2019 through June 2023; Infystem Holdings, Inc., a publicly traded provider of infion pumps and related products and services, from April 2012 through May 2019; Analogic Corporation, a private healthcare and security technology solutions company, from October 2017 through June 2018; PRGX Global, Inc., a private provider of recovery audit and spend analytics services, from February 2013 to March 2021; Spark Networks, a private operator of premium online dating sites and mobile applications, from July 2021 to February 2024; and Air Methods Corp., a private air medical transportation and air tism company, from March 2016 through April 2017. Mr. Whitters has also been an advisor or board member of several private companies. Mr. Whitters holds a B.A. in Accounting from Luther College.
高管简历
中英对照 | 中文 | 英文- R. Jason Richey
R.Jason Richey自2019年7月8日起担任我们的总裁。在担任总裁之前，里奇先生自2018年7月9日起担任首席运营官。在Reinstein先生于2019年1月4日辞职后，Richey先生还担任公司的临时总裁兼首席执行官，直到2019年7月8日。在加入Cutera之前，Richey先生曾担任LivaNova，PLC的北美总裁，该公司是一家价值50亿美元的全球医疗设备制造商，总部位于英国伦敦，在全球110多个国家和地区设有分支机构。通过Cyberonics Inc.和Sorin SpA的合并，Richey先生加入了Livanova。任职LivaNova/Cyberonics公司17年期间，他曾担任公司的多种职务，责任越来越大，包括:全球销售、营销、市场准入和政府事务副总裁、神经调节特许经营总裁兼总经理、北美地区总裁。在Cyberonics，Richey先生担任公司国际业务的副总裁兼总经理。他的医疗设备职业生涯始于任职B Braun Medical公司，从事销售和销售管理。Richey先生拥有印第安纳大学生物学学士学位。
R. Jason Richey has served on Board of Directors since December 2024. Currently Mr. Richey is President and CEO of Magnolia Medical Technologies, a privately held medical device company based in Seattle, WA ("Magnolia") since July 2025. Prior to Magnolia, Mr. Richey served as president and chief executive officer of Cytrellis Biosystems, Inc. ("Cytrellis") from June 2022 to October 2024. Prior to his time at Cytrellis, he served as president of Cutera, Inc. (Nasdaq: CUTR) ("Cutera") from July 2018 to June 2021. Prior to serving as Cutera's president, Mr. Richey served as Cutera's chief operating officer since July 9, 2018. Mr. Richey also served as Cutera's interim president and chief executive officer from January 4, 2019 until July 8, 2019. Immediately prior to joining Cutera, Mr. Richey served as the President of North America, for LivaNova, PLC, a $5 billion global medical device manufacturer headquartered in London, England with presence in more than 110 countries worldwide. Mr. Richey joined LivaNova via the merger of Cyberonics Inc. and Sorin SpA. During his 17 year tenure with LivaNova/Cyberonics, he served the company in multiple positions of increasing responsibility, including: Vice President of Global Sales, Marketing, Market Access, and Government Affairs, President & General Manager of the Neuromodulation Franchise, and Regional President, North America. At Cyberonics, among other roles, Mr. Richey served as the Vice President and General Manager of the company's international biness. Mr. Richey began his medical device career at B Braun Medical in sales and sales management. Mr. Richey holds a B.A. in Biology from Indiana University.- R.Jason Richey自2019年7月8日起担任我们的总裁。在担任总裁之前，里奇先生自2018年7月9日起担任首席运营官。在Reinstein先生于2019年1月4日辞职后，Richey先生还担任公司的临时总裁兼首席执行官，直到2019年7月8日。在加入Cutera之前，Richey先生曾担任LivaNova，PLC的北美总裁，该公司是一家价值50亿美元的全球医疗设备制造商，总部位于英国伦敦，在全球110多个国家和地区设有分支机构。通过Cyberonics Inc.和Sorin SpA的合并，Richey先生加入了Livanova。任职LivaNova/Cyberonics公司17年期间，他曾担任公司的多种职务，责任越来越大，包括:全球销售、营销、市场准入和政府事务副总裁、神经调节特许经营总裁兼总经理、北美地区总裁。在Cyberonics，Richey先生担任公司国际业务的副总裁兼总经理。他的医疗设备职业生涯始于任职B Braun Medical公司，从事销售和销售管理。Richey先生拥有印第安纳大学生物学学士学位。
- R. Jason Richey has served on Board of Directors since December 2024. Currently Mr. Richey is President and CEO of Magnolia Medical Technologies, a privately held medical device company based in Seattle, WA ("Magnolia") since July 2025. Prior to Magnolia, Mr. Richey served as president and chief executive officer of Cytrellis Biosystems, Inc. ("Cytrellis") from June 2022 to October 2024. Prior to his time at Cytrellis, he served as president of Cutera, Inc. (Nasdaq: CUTR) ("Cutera") from July 2018 to June 2021. Prior to serving as Cutera's president, Mr. Richey served as Cutera's chief operating officer since July 9, 2018. Mr. Richey also served as Cutera's interim president and chief executive officer from January 4, 2019 until July 8, 2019. Immediately prior to joining Cutera, Mr. Richey served as the President of North America, for LivaNova, PLC, a $5 billion global medical device manufacturer headquartered in London, England with presence in more than 110 countries worldwide. Mr. Richey joined LivaNova via the merger of Cyberonics Inc. and Sorin SpA. During his 17 year tenure with LivaNova/Cyberonics, he served the company in multiple positions of increasing responsibility, including: Vice President of Global Sales, Marketing, Market Access, and Government Affairs, President & General Manager of the Neuromodulation Franchise, and Regional President, North America. At Cyberonics, among other roles, Mr. Richey served as the Vice President and General Manager of the company's international biness. Mr. Richey began his medical device career at B Braun Medical in sales and sales management. Mr. Richey holds a B.A. in Biology from Indiana University.
- Rohan Seth
Rohan Seth自2020年8月10日起担任我们的首席财务官。在担任首席财务官之前，Seth先生于2019年2月至2020年2月担任Smith and Nephew全球骨科特许经营的财务副总裁。在2015年7月至2019年1月被任命为Smith&Nephew之前，Seth先生是Alcon Labs美国外科部门的财务主管，该公司是白内障，玻璃体视网膜手术和LASIK手术的全球领导者。在加入爱尔康之前，Seth先生从2006年7月到2015年7月在史赛克公司（全球医疗设备领导者）担任了9年的多个职位，其中包括SR。Stryker欧洲公司财务规划和分析总监。在Stryker任职之前，Seth从2003年6月到2006年7月在惠而浦公司工作。Seth先生以商业学士学位从孟买大学毕业后，获得了圣母大学的工商管理硕士学位。他也是the Institute of Chartered Accountants of India的特许会计师。
Rohan Seth has served as our Chief Financial Officer since August 10 2020. Prior to serving as CFO, from February 2019 to February 2020 Mr. Seth served as Vice-President of Finance for the Global Orthopaedics Franchise at Smith and Nephew. Prior to his assignment at Smith & Nephew, from July 2015 to January 2019 Mr. Seth was the Head of Finance for the U.S. Surgical division of Alcon Labs, a global leader in cataract, vitreoretinal and lasik surgery. Prior to Alcon, Mr. Seth held several positions of increasing responsibility at Stryker Corporation, a global medical device leader, over a period of nine years from July 2006 to July 2015 including Sr. Director, Financial Planning and Analysis and Controller, Stryker Europe. Prior to his roles at Stryker, Mr. Seth worked at Whirlpool Corporation from June 2003 to July 2006. Mr. Seth received his Master of Business Administration degree from the University of Notre Dame after graduating from the University of Mumbai as a Bachelor of Commerce. He is also Chartered Accountant from the Institute of Chartered Accountants of India.- Rohan Seth自2020年8月10日起担任我们的首席财务官。在担任首席财务官之前，Seth先生于2019年2月至2020年2月担任Smith and Nephew全球骨科特许经营的财务副总裁。在2015年7月至2019年1月被任命为Smith&Nephew之前，Seth先生是Alcon Labs美国外科部门的财务主管，该公司是白内障，玻璃体视网膜手术和LASIK手术的全球领导者。在加入爱尔康之前，Seth先生从2006年7月到2015年7月在史赛克公司（全球医疗设备领导者）担任了9年的多个职位，其中包括SR。Stryker欧洲公司财务规划和分析总监。在Stryker任职之前，Seth从2003年6月到2006年7月在惠而浦公司工作。Seth先生以商业学士学位从孟买大学毕业后，获得了圣母大学的工商管理硕士学位。他也是the Institute of Chartered Accountants of India的特许会计师。
- Rohan Seth has served as our Chief Financial Officer since August 10 2020. Prior to serving as CFO, from February 2019 to February 2020 Mr. Seth served as Vice-President of Finance for the Global Orthopaedics Franchise at Smith and Nephew. Prior to his assignment at Smith & Nephew, from July 2015 to January 2019 Mr. Seth was the Head of Finance for the U.S. Surgical division of Alcon Labs, a global leader in cataract, vitreoretinal and lasik surgery. Prior to Alcon, Mr. Seth held several positions of increasing responsibility at Stryker Corporation, a global medical device leader, over a period of nine years from July 2006 to July 2015 including Sr. Director, Financial Planning and Analysis and Controller, Stryker Europe. Prior to his roles at Stryker, Mr. Seth worked at Whirlpool Corporation from June 2003 to July 2006. Mr. Seth received his Master of Business Administration degree from the University of Notre Dame after graduating from the University of Mumbai as a Bachelor of Commerce. He is also Chartered Accountant from the Institute of Chartered Accountants of India.
- David H. Mowry
David H. Mowry，2013年2月至今，担任本公司的总裁、首席执行官；2013年6月至今，担任执行董事。他于2011年7月加入本公司，担任首席运营官；2012年11月，他被任命为临时总裁、首席执行官；2013年2月，正式担任总裁、首席执行官。他有着超过24年的医疗器械行业的经验。加入本公司之前，2010年7月至2011年7月，他担任Covidien plc的全球神经血管部门总裁，这是一个国际性的医疗产品供应商。2010年1月至2010年7月，他担任ev3 Inc的高级副总裁、全球心血管总裁，这是一个全球性的血管内置产品供应商，在2010年7月被Covidien收购。2007年8月至2010年1月，他是ev3的全球运营高级副总裁。此前，2006年11月至2007年10月，他担任ev3心血管理运营副总裁。加入ev3之前，2002年2月至2006年11月，他在 Zimmer Holdings的Zimmer Spine分部担任运营与物流副总裁，这是一个重建与脊柱植入物、外伤及相关整形外科产品的公司。加入Zimmer之前，他是医疗器械公司HeartStent Corp的总裁、首席运营官。他毕业于纽约的United States Military Academy in West Point，获得工程与数学学位。
David H. Mowry was appointed as the Company's Chief Executive Officer and a member of the Board on July 8 2019. Prior to joining Cutera, from May 2016 to October 2018 Mr. Mowry served as President and Chief Executive Officer, as well as a member of the Board of Directors, of Vyaire Medical, a global leader in the respiratory diagnostics, ventilation, and anesthesia delivery and patient monitoring market segments. Prior to his assignment at Vyaire, Mr. Mowry served as Executive Vice President and Chief Operating Officer and member of the Board of Directors of Wright Medical Group N.V., a global medical device company focused on extremities and biologics products, from October 2015 to May 2016 and during this time period he was also a member of the Board of Directors of EndoChoice Holdings, Inc., a company focused on the manufacturing and commercialization of platform technologies relating to the treatment of gastrointestinal conditions. Prior to Mr. Mowry's assignment at Wright Medical Group, he served as President and Chief Executive Officer and member of the Board of Directors of Tornier N.V. from February 2013 until October 2015 at which time Tornier and Wright Medical Group merged, and prior to that, as Chief Operating Officer of Tornier from 2011 to 2013. Within the spine industry, Mr. Mowry served as Vice President of Operations and Logistics at Zimmer Spine from February 2002 until October 2006. Mr. Mowry has held executive leadership positions over his thirty year medical device career at Covidien plc, ev3 Inc. and Zimmer Spine, Inc. Mr. Mowry is on the Board of directors of Alphatec Holdings, Inc., a public medical technology company that designs, develops, and markets products for the surgical treatment of spine disorders. Mr. Mowry received a B.S. degree in Engineering from the United States Military Academy at West Point.- David H. Mowry，2013年2月至今，担任本公司的总裁、首席执行官；2013年6月至今，担任执行董事。他于2011年7月加入本公司，担任首席运营官；2012年11月，他被任命为临时总裁、首席执行官；2013年2月，正式担任总裁、首席执行官。他有着超过24年的医疗器械行业的经验。加入本公司之前，2010年7月至2011年7月，他担任Covidien plc的全球神经血管部门总裁，这是一个国际性的医疗产品供应商。2010年1月至2010年7月，他担任ev3 Inc的高级副总裁、全球心血管总裁，这是一个全球性的血管内置产品供应商，在2010年7月被Covidien收购。2007年8月至2010年1月，他是ev3的全球运营高级副总裁。此前，2006年11月至2007年10月，他担任ev3心血管理运营副总裁。加入ev3之前，2002年2月至2006年11月，他在 Zimmer Holdings的Zimmer Spine分部担任运营与物流副总裁，这是一个重建与脊柱植入物、外伤及相关整形外科产品的公司。加入Zimmer之前，他是医疗器械公司HeartStent Corp的总裁、首席运营官。他毕业于纽约的United States Military Academy in West Point，获得工程与数学学位。
- David H. Mowry was appointed as the Company's Chief Executive Officer and a member of the Board on July 8 2019. Prior to joining Cutera, from May 2016 to October 2018 Mr. Mowry served as President and Chief Executive Officer, as well as a member of the Board of Directors, of Vyaire Medical, a global leader in the respiratory diagnostics, ventilation, and anesthesia delivery and patient monitoring market segments. Prior to his assignment at Vyaire, Mr. Mowry served as Executive Vice President and Chief Operating Officer and member of the Board of Directors of Wright Medical Group N.V., a global medical device company focused on extremities and biologics products, from October 2015 to May 2016 and during this time period he was also a member of the Board of Directors of EndoChoice Holdings, Inc., a company focused on the manufacturing and commercialization of platform technologies relating to the treatment of gastrointestinal conditions. Prior to Mr. Mowry's assignment at Wright Medical Group, he served as President and Chief Executive Officer and member of the Board of Directors of Tornier N.V. from February 2013 until October 2015 at which time Tornier and Wright Medical Group merged, and prior to that, as Chief Operating Officer of Tornier from 2011 to 2013. Within the spine industry, Mr. Mowry served as Vice President of Operations and Logistics at Zimmer Spine from February 2002 until October 2006. Mr. Mowry has held executive leadership positions over his thirty year medical device career at Covidien plc, ev3 Inc. and Zimmer Spine, Inc. Mr. Mowry is on the Board of directors of Alphatec Holdings, Inc., a public medical technology company that designs, develops, and markets products for the surgical treatment of spine disorders. Mr. Mowry received a B.S. degree in Engineering from the United States Military Academy at West Point.